Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 7, 2007, Pages 661-667

  Mühl, Diána ^a   Füredi, Réka ^a   Gecse, Krisztián ^a   Ghosh, Subhamay ^a   Falusi, Boglárka ^a   Bogár, Lajos ^a   Roth, Elisabeth ^a   Lantos, János ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Platelet function; Pulmonary embolism; Thrombolytic agents; Thrombosis

Indexed keywords

ADRENALIN; ALTEPLASE; D DIMER; FIBRINOGEN; STREPTOKINASE;

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; BLOOD SALVAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; MIDDLE AGED; PLATELET AGGREGATION; PULMONARY EMBOLISM; RECOMBINANT PROTEINS; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 34748842619     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3282e38e61     Document Type: Article

References (36)

1. Janata K, Holzer M, Domanovits H, Mullner M, Bankier A, Kurtaran A, et al. Mortality of patients with pulmonary embolism. Wien Klin Wochenschr 2002; 114:766-772.
2. Büchner S, Pfeiffer B, Hachenberg TH. Lungenembolie (CME 1/2/2005). Anästh Intensivmed 2005; 46:9-22.
3. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation 2006; 113:577-582.
4. Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism. Results of a multicenter registry. Circulation 1997; 96:882-888.
5. Meneveau N, Ming LP, Seronde MF, Mersin N, Schiele F, Caulfield F, et al. In hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur Heart J 2003; 24:1447-1454.
6. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperation Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386-1389.
7. Torbicki A, van Beek EJR, Charbonnier B, Meyer G, Morpurgo M, Palla A, et al., core writing group. Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 2000; 21:1301-1336.
8. Yoshida S, Kohro S, Yamakage M, Nakayama M, Namiki A. A case of suspected pulmonary thrombosis in a patient with reactive thrombocytemia who underwent liver subsegment ectomy. Masui 2003; 52:1320-1322.
9. Sobieszczyk P, Fishbein MC, Goldhaber SZ. Acute pulmonary embolism. Don't ignore the platelet. Circulation 2002; 106:1748-1749.
10. Stratmann G, Gregory GA. Neurogenic and humoral vasoconstriction in acute pulmonary thromboembolism. Anesth Analg 2003; 97:341-354.
11. Martin M, Eikerling B. Tödliche Lungenembolie unter Ultra-hoch-dosierter Streptokinase-Behandlung [letter]. Dtsch Med Wochenschr 1990; 115:1812.
12. Sárosi I, Mühl D, Tekeres M. What to do in 1998? The urgent lifesaving nonsurgical treatment of subtotal pulmonary embolism. In: XIII World Congress of Cardiology; 26-30 April 1998; Rio de Janeiro, Brazil. Bolognia: Monduzzi Editore S.p.A.; 1998. pp. 1019-1023.
13. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341:507-511.
14. Goldhaber SZ. Pulmonary embolism thrombolysis: broadening the paradigm for its administration. Circulation 1997; 96:716-718.
15. Goldhaber SZ, Elliott CG. Acute pulmonary embolism: Part II: risk stratification, treatment, and prevention. Circulation 2003; 108:2834-2838.
16. Perrier A, Roy PM, Sanchez O, Le Gal G, Meyer G, Gourdier AL, et al. Multidetector-row computed tomography in suspected pulmonary embolism. N Engl J Med 2005; 352:1760-1768.
17. Perrier A, Roy PM, Aujesky D, Chagnon I, Howarth N, Gourdier AL, et al. Diagnosing pulmonary embolism in outpatients with clinical assessment, D-dimer measurement, venous ultrasound, and helical computed tomography: a multicenter management study. Am J Med 2004; 116:291-299.
18. Gabbasov ZA, Gavrilov IY, Popov EG. The use of optical density fluctuations for determination of platelet concentration in stirred suspension. Platelets 1992; 3:281-282.
19. Maaroufi RM, Giordano P, Triadou P, Tapon-Bretaudiere J, Dautzenberg MD, Fischer AM. Effect of oversulfated dermatan sulfate derivatives on platelet aggregation. Thromb Res 2007. [Epub ahead of print]
20. Liu P, Meneveau N, Schiele F, Bassan JP. Predictors of long-term clinical outcome of patients with acute massive pulmonary embolism after thrombolytic therapy. Chin Med J (Engl) 2002; 116:503-509.
21. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism. A meta-analysis of the randomized controlled trials. Circulation 2004; 110:744-749.
22. Weltermann A, Eichinger S, Bialonczyk C, Minar E, Hirschl M, Quehenberger P, et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost 2002; 1:28-32.
23. Gurbel PA, Hayes K, Bliden KP, Yoho J, Tantry US. The platelet-related effects of tenetecteplase versus alteplase versus reteplase. Blood Coagul Fibrinolysis 2005; 16:1-7.
24. Serebruany VL, Malini AI, Callahan KP, Binbrek A, Van De Werf F, Alexander JH, et al. Effect of tenetecteplase versus alteplase on platelets during the first 3 h of treatment for acute myocardial infarction: the Assesment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. Am Heart J 2003; 145:636-642.
25. Alt E, Amann-Vesti BR, Madl C, Funk G, Koppensteiner R. Platelet aggregation and blood rheology in severe septic shock: relation to the Sepsis-related Organ Failure Assessment (SOFA) score. Clinic Hemorrh Microsc 2004; 30:107-115.
26. Moser M, Nordt T, Peter K, Ruef J, Kohler B, Schmittner M, et al. Platlet function during and after thrombolytic therapy for acut myocardial infarction with reteplase, alteplase, or streptokinase. Circulation 1999; 100:1858-1864.
27. Gurbel PA, Serebruany VL, Shustov AR, Bahr RD, Carpo C, Ohman EM, et al. Effect of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 h of acute myocardial infarction treatment. GUSTO-III Investigators. J Am Coll Cardiol 1998; 31:1466-1473.
28. Korbut R, Gryglewski RJ. Platelets in fibrinolytic system. J Physiol Pharmacol 1995; 46:409-418.
29. Peter K, Kohler B, Straub A, Ruef J, Moser M, Nordt T, et al. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. Circulation 2000; 102:1490-1496.
30. Szabo S, Etzel D, Ehlers R, Walter T, Kazmaier S, Helber U, et al. Combined thrombolysis with abciximab favourably influences platelet-leukocyte interactions and platelet activation in acute myocardial infarction. J Thromb Thrombolysis 2005; 20:155-161.
31. Szabo S, Etzel D, Ehlers R, Walter T, Kazmaier S, Helber U, et al. Increased fibrin specificity and reduced paradoxical thrombin activation of the combined thrombolytic regimen with reteplase and abciximab versus standard reteplase thrombolysis. Drugs Exp Clin Res 2004; 30:47-54.
32. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998; 97:211-218.
33. Agnelli G, Parise P. Bolus thrombolysis in venous thromboembolism. Chest 1992; 101 (4 Suppl):172-182.
34. Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, Barbash GI, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001; 104:1229-1235.
35. Goldhaber SZ. Modern treatment of pulmonary embolism. Eur Respir J Suppl 2002; 35:22-27.
36. Aklog L, Williams CS, Byrne JG, Goldhaber SZ. Acute pulmonary embolectomy: a contemporary approach. Circulation 2002; 105:1416-1419.